The University of Pittsburgh and University of Pittsburgh Cancer Institute propose to conduct a Specialized Program of Research Excellence (SPORE) in Skin Cancer. The overall goals of the University Pittsburgh Skin Cancer SPORE are to improve the detection and treatment of skin cancer. The SPORE program will consist of six translational research projects in skin cancer, four cores including an administrative core, a developmental research program and a career development program. The University of Pittsburgh Skin Cancer SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co- investigators in basic, applied and clinical science. It is also organ-specific in that its approach and all projects will test hypotheses about skin cancer biology, susceptibility, detection, or treatment. The long-term translational research projects that will serve as the basis for improving the outcome of patients diagnosed with skin cancer. The six main projects include: (1) Chemoprevention of Melanoma with Sulforaphane;(2) Multiple Antigen-Engineered DC Immunization and IFN? Boost for Metastatic Melanoma;(3) Polarized Dendritic Cells Guide Melanoma-Specific Responses;(4) Therapeutic Immune Targeting of EphA2 Expressed by Melanoma and Its Tumor-Associated Vasculature;(5) Delineating the DNA Repair pathways impacting alkylating agent efficacy in the treatment of Melanoma;(6) Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-regs depletion. The four research cores will interact closely to assist the main research projects, developmental research projects and the career development investigators in carrying out translational skin cancer research. The research cores are: Core A. Administrative Core;Core B. Tissue Core;Core C. Immunological Monitoring and Cellular Products Laboratory (IMCPL);Core D. Biostatics. The Administrative Core will solicit feedback from the Internal and External Scientific Advisory Boards and provide scientific, regulatory and fiscal oversight for the SPORE program. The Skin SPORE investigators will work together to synergistically achieve the goals of the program and will also interact with investigators from SPOREs at other institutions to improve the outcome of patients with skin cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-05
Application #
8329701
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Program Officer
Agarwal, Rajeev K
Project Start
2008-08-26
Project End
2013-07-31
Budget Start
2012-09-10
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$2,300,000
Indirect Cost
$851,827
Name
University of Pittsburgh
Department
Dermatology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Anderson, Alyce J M; Ferris, Laura K; Binion, David G et al. (2018) Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci 63:2564-2572
Geskin, Larisa J; Damiano, James J; Patrone, Christina C et al. (2018) Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res 28:211-221
Geskin, Larisa J; Akilov, Oleg E; Kwon, Soonyou et al. (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67:423-434
Davar, Diwakar; Wang, Hong; Chauvin, Joe-Marc et al. (2018) Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol :JCO1800632
Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739
Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190
Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449

Showing the most recent 10 out of 209 publications